Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 9 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:55 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 3, 2026 | Mar 4, 2025 | Feb 22, 2024 | Mar 13, 2023 |
| Revenue | $0 | $87.4M | $380.8M | $22.2M |
| Cost of revenue | $0 | $5.95M | $25.4M | $2.99M |
| Research and development | $90.4M | $104.1M | $128.2M | $93.5M |
| Selling, general and administrative | $62.9M | $114.3M | $188.4M | $127.1M |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M |
| Income tax | $46.0K | -$393.0K | $5.03M | $774.0K |
| Net income | -$144.7M | -$301.7M | $49.3M | -$198.4M |
| EPS, basic | $-1.53 | $-4.43 | $0.73 | $-3.39 |
| EPS, diluted | $-1.53 | $-4.43 | $0.70 | $-3.39 |
| Weighted shares, basic | 94.6M | 68.1M | 67.2M | 58.5M |
| Weighted shares, diluted | 94.6M | 68.1M | 70.0M | 58.5M |
| Margins and growth | ||||
| Operating margin | – | -360.2% | 10.2% | -905.7% |
| Net margin | – | -345.4% | 12.9% | -892.4% |
| Revenue growth, year over year | −100.0% | −77.1% | +1,612.9% | – |
| Net income growth, year over year | – | −712.4% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 3, 2026 | Mar 4, 2025 | Feb 22, 2024 | Mar 13, 2023 |
| Cash and equivalents | $226.7M | $77.4M | $170.2M | $62.5M |
| Short-term investments | $90.3M | $99.1M | $201.2M | $284.4M |
| Accounts receivable | $88.0K | $447.0K | $40.0M | $15.3M |
| Inventory | – | – | $38.3M | $9.77M |
| Total current assets | $323.7M | $189.4M | $464.7M | $382.1M |
| Property, plant and equipment | $310.0K | $961.0K | $2.69M | $2.61M |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M |
| Accounts payable | $3.52M | $2.94M | $22.1M | $6.26M |
| Total current liabilities | $22.7M | $28.4M | $82.0M | $46.6M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M |
| Shareholders' equity | $305.3M | $164.8M | $433.4M | $340.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 3, 2026 | Mar 4, 2025 | Feb 22, 2024 | Mar 13, 2023 |
| Operating cash flow | -$123.3M | -$167.6M | $11.9M | -$179.9M |
| Capital expenditures | $138.0K | $157.0K | $1.24M | $2.53M |
| Free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M |
| Stock-based compensation | $27.6M | $33.0M | $37.2M | $21.7M |
| Investing cash flow | $14.0M | $75.7M | $92.1M | -$239.0M |
| Financing cash flow | $257.0M | $348.0K | $3.54M | $431.8M |
| Net change in cash | $148.8M | -$92.1M | $107.7M | $12.9M |
| Ratio | ||||
| Stock-based compensation, % of revenue | – | 37.8% | 9.8% | 97.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 128.6M | +17.1% | SEC |
| Jul 27, 2026 | 111.4M | +25.0% | SEC |
| Apr 27, 2026 | 111.2M | +24.7% | SEC |
| Feb 23, 2026 | 110.5M | +24.8% | SEC |
| Oct 27, 2025 | 109.8M | +60.2% | SEC |
| Jul 28, 2025 | 89.2M | +31.0% | SEC |
| Apr 28, 2025 | 89.1M | +31.1% | SEC |
| Feb 28, 2025 | 88.6M | +30.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.